All In Biotech

Drug Trial Radar · NCT00486200

A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes

Last checked: Nov 19, 2026Latest source record: Dec 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 695 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

695

Actual

Start

Jun 21, 2007

Primary completion

Aug 12, 2008

Study completion Aug 12, 2008

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jun 14, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.

Conditions

  • Herpes Genitalis

Interventions

  • ASP2151Drug

    Oral administration.

  • valacyclovirDrug

    Oral administration of active comparator.

  • PlaceboDrug

    Oral administration of placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the efficacy and safety of ASP2151 with valacyclovir and placebo in the acute treatment of recurrent genital Herpes Simplex Virus InfectionTime frame: 17 days

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Westlake Village, California

  • Site not named

    Denver, Colorado

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Madisonville, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Billings, Montana

  • Site not named

    Omaha, Nebraska

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Arlington, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Annandale, Virginia

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.